BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cystic Fibrosis readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Cystic Fibrosis\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05331183-10838@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20270406
DTEND;VALUE=DATE:20270407
SUMMARY:Trikafta (Elexacaftor / tezacaftor / ivacaftor): Phase 3 readout es
 t. (NCT05331183)
DESCRIPTION:Trikafta (Elexacaftor / tezacaftor / ivacaftor)\, phase 3\, Cys
 tic Fibrosis.\nStudy: Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (
 ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del\nEs
 timated primary completion: 6 April 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/elexacaftor-tezacaftor-ivacaftor#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05331183
URL:https://assetmemo.bio/drug/elexacaftor-tezacaftor-ivacaftor#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06460506-10838@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Trikafta (Elexacaftor / tezacaftor / ivacaftor): Phase 3 readout es
 t. (NCT06460506)
DESCRIPTION:Trikafta (Elexacaftor / tezacaftor / ivacaftor)\, phase 3\, Cys
 tic Fibrosis.\nStudy: Evaluation of Long-term Safety and Efficacy of ELX/T
 EZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older\nEstimat
 ed primary completion: 30 September 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/elexacaftor-tezacaftor-ivacaftor#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06460506
URL:https://assetmemo.bio/drug/elexacaftor-tezacaftor-ivacaftor#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05844449-10837@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20290730
DTEND;VALUE=DATE:20290731
SUMMARY:Alyftrek (Vanzacaftor / tezacaftor / deutivacaftor): Phase 3 readou
 t est. (NCT05844449)
DESCRIPTION:Alyftrek (Vanzacaftor / tezacaftor / deutivacaftor)\, phase 3\,
  Cystic Fibrosis.\nStudy: Evaluation of Long-Term Safety and Efficacy of V
 anzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year
  of Age and Older\nEstimated primary completion: 30 July 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/vanzacaftor-tezacaftor-deutivaca
 ftor#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05844449
URL:https://assetmemo.bio/drug/vanzacaftor-tezacaftor-deutivacaftor#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05422222-10837@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Alyftrek (Vanzacaftor / tezacaftor / deutivacaftor): Phase 3 readou
 t est. (NCT05422222)
DESCRIPTION:Alyftrek (Vanzacaftor / tezacaftor / deutivacaftor)\, phase 3\,
  Cystic Fibrosis.\nStudy: Evaluation of VX-121/Tezacaftor/Deutivacaftor in
  Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age\nEstimated pr
 imary completion: 30 June 2030. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/vanzacaftor-tezacaftor-deutivacaftor#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05422222
URL:https://assetmemo.bio/drug/vanzacaftor-tezacaftor-deutivacaftor#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
